1-(3,4-Dibromo-benzyl)-piperazine → 4-(3,4-Dibromo-benzyl)-piperazine-1-carboxylic acid pyrimidin-4-ylamide
반응식
C1(O[C:8](=[O:16])[NH:9][C:10]2[CH:15]=[CH:14][N:13]=[CH:12][N:11]=2)C=CC=CC=1.[Br:17][C:18]1[CH:19]=[C:20]([CH:28]=[CH:29][C:30]=1[Br:31])[CH2:21][N:22]1[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]1>>[N:13]1[CH:14]=[CH:15][C:10]([NH:9][C:8]([N:25]2[CH2:24][CH2:23][N:22]([CH2:21][C:20]3[CH:28]=[CH:29][C:30]([Br:31])=[C:18]([Br:17])[CH:19]=3)[CH2:27][CH2:26]2)=[O:16])=[N:11][CH:12]=1참가 물질
3
실험 절차
The title compound was prepared from pyrimidin-4-yl-carbamic acid phenyl ester and 1-(3,4-dibromo-benzyl)-piperazine in analogy with Example 142. 1H NMR (400 MHz, CDCl3): 8.40 (s, 1H), 8.10-7.80 (m, 1H), 7.70-7.50 (m, 1H), 7.58-7.45 (m, 1H), 7.14-7.10 (m, 1H), 6.55-6.40 (m, 1H), 3.40 (s, 2H), 2.87 (t, J=4.8 Hz, 4H), 2.38 (t, J=4.8 Hz, 4H).
출처 및 근거
- ORD 기록
- ord-e633a5cb54cb46ca9d96a308c8110a2f
- 출처 데이터셋
- uspto-grants-2013_09